Most Promising Obesity Drugs After GLP-1: What Comes Next?
After the first GLP-1 wave, the most promising obesity drugs are not one single class. They are the best examples of four lanes: triple agonists, oral GLP-1s, amylin-pathway drugs, and the rare non-incretin asset that looks commercially real.
Why this matters
This is the big framing page for readers trying to understand what the second and third waves of obesity medicine actually look like.
Current read
Retatrutide still defines the next efficacy ceiling. Orforglipron defines the next access story. Amycretin and CagriSema define the satiety and amylin extension story. Bimagrumab and a handful of non-incretin names matter because the market eventually needs more than incretin repetition.
Primary query
most promising obesity drugs after glp1
Page type
Pipeline Theme
Lead read
Retatrutide
Stage mix
3 phase 3 · 2 filed / decision-stage · 1 phase 2
Pipeline facts for search and AI answers
What this pipeline theme page answers
Primary query
most promising obesity drugs after glp1
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Pipeline Theme
This page answers a focused pipeline question and connects it to the compounds, timelines, and comparisons that matter most.
Lead read
Retatrutide
Retatrutide still defines the next efficacy ceiling. Orforglipron defines the next access story. Amycretin and CagriSema define the satiety and amylin extension story. Bimagrumab and a handful of non-incretin names matter because the market eventually needs more than incretin repetition.
Stage mix
3 phase 3 · 2 filed / decision-stage · 1 phase 2
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
Retatrutide is a phase 3 program from Eli Lilly built around GLP-1/GIP/Glucagon.
Why does it matter?
After the first GLP-1 wave, the most promising obesity drugs are not one single class. They are the best examples of four lanes: triple agonists, oral GLP-1s, amylin-pathway drugs, and the rare non-incretin asset that looks commercially real.
What should you read next?
What we know right now
After the first GLP-1 wave, the most promising obesity drugs are not one single class. They are the best examples of four lanes: triple agonists, oral GLP-1s, amylin-pathway drugs, and the rare non-incretin asset that looks commercially real.
Retatrutide still defines the next efficacy ceiling. Orforglipron defines the next access story. Amycretin and CagriSema define the satiety and amylin extension story. Bimagrumab and a handful of non-incretin names matter because the market eventually needs more than incretin repetition.
Right now this page is anchored by Retatrutide, Orforglipron, Amycretin (Zenagamtide), which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Which lane proves it can do more than extend the current GLP-1 playbook
- Whether the category starts caring more about body composition, convenience, and liver outcomes
- How quickly the market narrows this list to a few real winners
Decision path
How should I interpret Most Promising Obesity Drugs After GLP-1: What Comes Next??
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- most promising obesity drugs after glp1
- Type
- Pipeline Theme
- Tracked names
- 6
- Stage mix
- 3 phase 3 · 2 filed / decision-stage · 1 phase 2
Step 1
Check maturity
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
Step 2
Watch the next signal
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 | Read status page |
| Orforglipron | Eli Lilly | Oral GLP-1 | FDA April 2026 | Read status page |
| Amycretin (Zenagamtide) | Novo Nordisk | GLP-1/Amylin | Phase 3 | Read status page |
| CagriSema | Novo Nordisk | GLP-1 + Amylin/Calcitonin | FDA-filed | Read status page |
| Bimagrumab | Eli Lilly/Versanis | ActRII antagonist | Phase 2b | Read status page |
| Survodutide | Boehringer/Zealand | GLP-1/Glucagon | Phase 3 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Non-incretin mechanisms
Bimagrumab
Eli Lilly/Versanis · Phase 2b
ActRII antagonist
Related comparisons
Retatrutide vs MariTide: Category-Leading Triple Agonist vs Amgen's Differentiation Bet
Retatrutide is the cleaner bet on late-stage leadership. MariTide is the cleaner bet on differentiated disruption. Retatrutide looks more obvious today. MariTide only wins this discussion if the market decides it wants something that feels genuinely different rather than merely stronger.
Orforglipron vs Amycretin: Oral Scale Story vs Novo's Amylin-Franchise Bet
Orforglipron is the bigger broad-market adoption story. Amycretin is the bigger franchise strategy story. If the question is which asset could touch more patients faster, it is orforglipron. If the question is which one matters more to Novo's identity after the first wave, it is amycretin.
Survodutide vs Amycretin: Glucagon-Linked Efficacy Bet vs Novo's Amylin Second Act
Survodutide is the more straightforward late-stage contender. Amycretin is the more strategic portfolio bet because it tells you where Novo wants the category to go next. Survodutide looks more direct. Amycretin looks more important to the future shape of Novo's obesity franchise.
Bimagrumab vs Taldefgrobep: Two Muscle-Preservation Obesity Bets Compared
Bimagrumab has the stronger sponsor context. Taldefgrobep has the cleaner single-pathway narrative. Both are meaningful because they are trying to solve a different problem than the incretin leaders: how to protect body composition, not just drive appetite down.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.